News
KALA
6.40
-2.53%
-0.17
Weekly Report: what happened at KALA last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at KALA last week (0408-0412)?
Weekly Report · 04/15 10:37
Weekly Report: what happened at KALA last week (0401-0405)?
Weekly Report · 04/08 10:40
Kala Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/02 15:57
Kala Pharmaceuticals Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
Dow Jones · 04/02 15:57
HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $21
Benzinga · 04/02 15:47
Buy Rating on Kala Pharmaceuticals Amidst Positive Clinical Developments and Strong Financial Position
TipRanks · 04/02 13:35
KALA BIO INC <KALA.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $21 FROM $22
Reuters · 04/02 13:29
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023
Kala Pharmaceuticals reported earnings per share of -$3.18 for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of - $3.62. Kala pharmaceuticals just reported results.
Investorplace · 04/02 11:53
Weekly Report: what happened at KALA last week (0325-0329)?
Weekly Report · 04/01 10:39
KALA BIO Inc reports results for the quarter ended in December - Earnings Summary
KALA BIO Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $3.18 per share. The mean expectation of three analysts was for a loss of £3.62 per share for the same quarter. Reported revenue was zero; analysts expected zero.
Reuters · 03/29 13:09
Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44
Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44. As of December 31, 2023, KALA had cash and cash equivalents of $50.9 million. The company is expected to fund operations into the third quarter of 2024.
Seeking Alpha · 03/29 12:34
BRIEF-Kala Pharmaceuticals Q4 EPS USD -3.18
Reuters · 03/29 12:00
Press Release: KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update. Advancing ongoing Phase 2b CHASE trial of KPI-012 for the treatment of persistent corneal epithelial defect. Topline data targeted by year-end 2024. KALA is exploring opportunities to expand K PI-012 into additional ocular indications.
Dow Jones · 03/29 12:00
*KALA BIO 4Q Loss/Shr $3.18 >KALA
Dow Jones · 03/29 12:00
Press Release: KALA BIO Reports Fourth Quarter -2-
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. The company's lead product candidate, KPI-012, is in clinical development for the treatment of persistent corneal epithelial defect. KALA reported a loss on extinguishment of debt for the full year of 2023.
Dow Jones · 03/29 12:00
Weekly Report: what happened at KALA last week (0318-0322)?
Weekly Report · 03/25 10:41
Weekly Report: what happened at KALA last week (0311-0315)?
Weekly Report · 03/18 10:40
Weekly Report: what happened at KALA last week (0304-0308)?
Weekly Report · 03/11 10:37
KALA Pharmaceuticals Spotlights Ophthalmology Advances
TipRanks · 03/04 12:42
More
Webull provides a variety of real-time KALA stock news. You can receive the latest news about Kala Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.